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ABSTRACT
Telomeres resemble common fragile sites (CFSs) in that they are difficult-to-
replicate and exhibit fragility in mitosis in response to DNA replication stress. At 
CFSs, this fragility is associated with a delay in the completion of DNA replication 
until early mitosis, whereupon cells are proposed to switch to a RAD52-dependent 
form of break-induced replication. Here, we show that this mitotic DNA synthesis 
(MiDAS) is also a feature of human telomeres. Telomeric MiDAS is not restricted to 
those telomeres displaying overt fragility, and is a feature of a wide range of cell 
lines irrespective of whether their telomeres are maintained by telomerase or by the 
alternative lengthening of telomeres (ALT) mechanism. MiDAS at telomeres requires 
RAD52, and is mechanistically similar to CFS-associated MiDAS, with the notable 
exception that telomeric MiDAS does not require the MUS81-EME1 endonuclease. 
We propose a model whereby replication stress initiates a RAD52-dependent form of 
break-induced replication that bypasses a requirement for MUS81-EME1 to complete 
DNA synthesis in mitosis.
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INTRODUCTION
Telomeres are the specialized DNA structures that cap 
the ends of linear chromosomes in eukaryotes. Although the 
sequence of telomeric DNA can differ amongst different 
organisms, the basic structure is conserved. In humans, 
each telomere comprises a long dsDNA tract of TTAGGG 
repeat units that terminates on the G-rich 3′-strand with a 
ssDNA overhang of variable length [1]. This 3′-overhang 
is proposed to loop back and invade into the double-
stranded telomeric repeat DNA to form a so-called T-loop, 
which resembles the D-loop generated as an intermediate 
during homologous recombination [2, 3]. Telomeric DNA 
in human cells is bound by the shelterin protein complex, 
which comprises TRF1, TRF2, RAP1, TIN2, TPP1, and 
POT1. Shelterin proteins serve to maintain the T-loop at 
telomeres and to ensure that chromosome ends are not 
mistaken for pathological dsDNA breaks, which ultimately 
suppresses excessive recombination between telomeres [1]. 
However, there is an apparent ‘price to pay’ for the 
unusual organizational structure at telomeres, in that the 
G-rich repeated sequence, together with its tightly bound 
shelterin proteins, form a formidable barrier to the smooth 
progression of DNA replication forks. This type of fork 
disruption is potentially more problematic within telomeres 
than elsewhere in the genome because the very end of the 
chromosome must be replicated unidirectionally from an 
internal replication origin, and hence a stalled replication 
fork cannot be rescued through merging with a converging 
fork [4]. 
Telomeres display a number of features that 
are shared with common fragile sites (CFSs). Most 
notably, telomeres and CFSs are defined as ‘difficult-to-
replicate’ loci. In both cases, these loci display structural 
abnormalities on metaphase chromosomes that are induced 
either by exposure of cells to the DNA polymerase 
inhibitor, aphidicolin (APH), or by interfering with the 
function of the replication stress kinase ATR [5–7]. 
                                                   Research Paper: Chromosome
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The manifestation of a problematic replication program at 
CFSs is their tendency to show gaps/breaks/uncondensed 
regions (denoted as ‘fragility’) on otherwise fully 
condensed metaphase chromosomes. In contrast, telomere 
fragility cannot be observed easily on conventional 
DAPI-stained metaphases. Instead, the detection of 
telomere fragility requires the use of fluorescence in situ 
hybridization (FISH) to reveal fragility, which usually 
takes the form of either multi-telomeric FISH signals 
or abnormally extended telomeres. The underlying 
mechanism for chromosome fragility is still debated, and 
might even differ at different loci. However, evidence 
has accumulated to suggest that the source of replication 
fork perturbation might be either the presence of a DNA 
secondary structure in the template (e.g. a hairpin or 
G-quartet) or because of a clash between the replisome and 
the transcription machinery [8].
In somatic cells, telomeres can shorten in length 
during every round of DNA replication due to the so-
called ‘end-replication problem’, which ultimately will 
limit cell proliferation if not rectified. This shortening 
necessitates the extension of the telomeric sequence, 
which can occur via either of two mechanisms. Stem 
cells and most cancer cells utilize the specialized reverse 
transcriptase, telomerase, to add additional TTAGGG 
repeat units to the short telomere using an intrinsic RNA 
primer [9]. Some cancer cells, however, use a homologous 
recombination-dependent process called the Alternative 
Lengthening of Telomeres (ALT) pathway [10]. Recently, 
the ALT pathway has been shown to involve a DNA repair 
process called break-induced replication (BIR) that has 
been characterized in detail only in yeast. This proposed 
telomeric BIR pathway depends upon the non-catalytic 
subunit of DNA Polymerase δ, POLD3, which is the 
human homolog of Pol32 required for BIR in yeast. This 
BIR-like process is seemingly suppressed in telomerase-
positive (henceforth denoted as telomerase+) cells, and 
therefore is restricted to ALT cells requiring recombination 
functions for the maintenance of telomere stability [11–13]. 
In this respect, the ALT pathway also shows similarity to 
the processes required for maintenance of CFS stability, 
because BIR has been implicated in the completion of 
DNA replication at CFSs after the cell has entered the 
prophase of mitosis. We have shown previously that a 
RAD52-, MUS81- and POLD3-dependent process termed 
MiDAS (for Mitotic DNA Synthesis) occurs at CFSs 
following replication stress [14, 15]. MiDAS at CFSs is 
unusual for a BIR-like event, in that it apparently does not 
require RAD51. Indeed, the function of RAD51 appears 
to suppress a requirement for MiDAS, suggesting that 
MiDAS might represent an atypical, sub-pathway of BIR, 
which serves to back-up conventional RAD51-dependent 
recombination occurring prior to mitosis.
In this study, we report that human cancer cells 
exhibit MiDAS at telomeres, which is enhanced in response 
to replication stress (low dose APH). Interestingly, this 
process is a feature of both ALT cells and telomerase+ cells, 
and is not restricted to telomeres that are overtly fragile. We 
also show that APH-induced telomeric MiDAS requires a 
similar, but not identical, set of DNA repair/recombination 
factors to those that promote CFS-associated MiDAS, 
highlighting telomeres as a specialized subset of CFSs. 
Given that oncogene-induced replication stress is a common 
feature of cancers, we propose that disrupting MiDAS 
could be a viable strategy to selectively kill malignant cells 
as it will target both telomerase+ and ALT tumors.
RESULTS
Mitotic DNA synthesis (MiDAS) occurs at 
telomeres
It has been shown previously that cells exposed 
to APH-induced DNA replication stress conduct BIR-
like DNA repair synthesis (MiDAS) at CFS loci in early 
mitosis [14–16]. Because APH-inducible fragility is also 
a characteristic of telomeres [7], we investigated whether 
DNA synthesis might still be occurring within telomeres 
during mitosis. To this end, we utilized an established 
EdU labelling method [14, 15] for quantifying MiDAS 
in U2OS cells that had been treated or not with a low 
dose of APH (0.4 μM) during S phase. We then analyzed 
sites of MiDAS on metaphase chromosomes using a 
combination of telomeric FISH and EdU detection using 
Click-IT chemistry. To ensure that we omitted examples 
of MiDAS occurring at CFSs fortuitously located close 
to a telomere, we only scored those EdU foci that co-
localized precisely with a telomeric FISH signal or that 
lay at the very tip of the chromosome distal to the FISH 
signal (Figure 1A). Using this approach, we could readily 
detect EdU incorporation at telomeres during mitosis that 
was strongly induced by exposure of the cells in S phase to 
APH (Figure 1B, 1C and Supplementary Figure 1A, 1B). 
Henceforth, we will refer to this as ‘telomeric MiDAS’. 
To confirm that this DNA synthesis was dependent upon 
conventional replicative polymerases, as has been shown 
for CFS-associated MiDAS, we exposed cells in mitosis 
to a high dose of APH (2 μM). As expected, telomeric 
MiDAS was abolished by high dose APH applied in 
mitosis (Figures 1C and Supplementary Figure 1A, 1B). 
We conclude that MiDAS occurs frequently at telomeres 
in U2OS cells undergoing replication stress.
MiDAS occurs at telomeres maintained by 
telomerase or ALT
The ALT pathway, like CFS-associated MiDAS, 
has been proposed to operate via a BIR-like process 
[11, 13]. Hence, we set out to determine whether telomeric 
MiDAS was limited to those cells utilizing ALT for 
their telomere maintenance. For this, we first analyzed 
HeLa cells, which express telomerase. We observed 
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that replication stress also induced telomeric MiDAS 
in HeLa cells, which was abrogated by high dose APH 
treatment in mitosis (Figure 1D, 1E and Supplementary 
Figure 1C, 1D). These data suggest that APH-induced 
telomeric MiDAS is not limited to ALT cells, and that 
the telomerase status of cells does not influence whether 
replication stress-induced MiDAS occurs at telomeres. 
To gain additional evidence in support of this contention, 
Figure 1: Replication stress induces mitotic DNA synthesis at telomeres in both ALT and telomerase+ cells. 
(A) Representative images of EdU (red) incorporation at telomeres (marked by telomeric FISH; green). Yellow arrows show those EdU foci 
that were scored either because of co-localization with the FISH signal or because the EdU focus lay beyond the tip of the chromosome. 
(B) Representative images of EdU (red) incorporation at telomeres (marked by telomeric FISH; green) on metaphase chromosomes (DAPI 
stained; blue) in APH-treated U2OS cells. (C) Quantification of EdU incorporation at telomeres on metaphase chromosomes in U2OS cells 
treated with or without low dose APH (0.4 μM) treatment in S phase. Where indicated, cells were exposed to high dose APH (2 μM) in mitosis. 
(D) Representative images of EdU (red) incorporation at telomeres (marked by telomeric FISH; green) on metaphase chromosomes (stained 
with DAPI; blue) in low dose APH-treated HeLa cells. (E) Quantification of EdU incorporation at telomeres on metaphase chromosomes 
from HeLa cells treated with or without low dose APH (0.4 μM). Where indicated, cells were exposed to high dose APH (2 μM) in mitosis. 
Data represent the means of at least three independent experiments. Error bars indicate SEM. See also Supplementary Figure 1.
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we quantified MiDAS in a panel of different ALT and 
telomerase+ cell lines. These lines also differ in their 
degree of aneuploidy and/or telomere length. This analysis 
confirmed that APH-induced telomeric MiDAS occurs 
not only in ALT cells, but also in cells with telomerase-
maintained telomeres (Figure 2A–2C and Supplementary 
Figure 2). Moreover, in a telomerase+ cell line, T98G, 
we observed a discernible level of telomeric MiDAS 
even in the absence of replication stress (Figure 2C). 
This feature, which is shared with the ALT cell lines, 
indicates that telomeric MiDAS occurring in the absence 
of exogenous replicative stress is also not restricted to ALT 
cell lines. We failed to detect significant levels of APH-
induced telomeric MiDAS in only one cell line, Saos-2, 
which is a near-diploid ALT cell line (Figure 2B). In a 
sub-clone of HeLa cells with abnormally long telomeres 
(HeLaLT) [17], we observed a significantly higher level 
of telomeric MiDAS than was detected in the parental 
HeLa cells, both in the presence and absence of replication 
stress (Figure 2C). We conclude that telomeric MiDAS 
occurs in a wide range of cancer cell lines irrespective 
of their mechanism of telomere maintenance. Moreover, 
neoplastic transformation per se is not a prerequisite for 
the existence of replication stress-induced MiDAS, as the 
VA13 fibroblast cell line also exhibited a robust level of 
MiDAS (Figure 2B). 
Telomeric MiDAS does not correlate with 
telomere fragility
We showed previously that CFS-associated MiDAS 
occurs frequently at the site of a visible gap/break in 
the metaphase chromosome. Hence, we analyzed the 
relationship between telomeric MiDAS and the presence 
or absence of overt telomere fragility. In the absence of 
APH, telomeric MiDAS was largely associated with 
fragile telomeres in U2OS cells. Nevertheless, despite 
the apparent similarities between telomere- and CFS-
associated MiDAS, there was no association between 
fragility and the appearance of telomeric MiDAS 
following APH treatment. On the contrary, telomeric 
MiDAS induced by APH more frequently occurred at 
telomeres that exhibited a normal gross morphology 
in both U2OS and HeLa cells (Figure 3A, 3B). Hence, 
it is clear that the presence of overt telomere fragility 
and MiDAS correlate poorly. As expected, considering 
that telomeric MiDAS is a phenomenon associated with 
replication stress, the inhibition of the ATR kinase using 
a small molecule inhibitor, VE-821, exacerbated the level 
of telomeric MiDAS in U2OS cells (Figure 3C, 3D, and 
Supplementary Figure 3). This compound has been shown 
previously to enhance fragility at both telomeres and CFSs 
[6, 7], and to promote MiDAS at CFSs [14]. We conclude 
that replication stress-induced telomeric MiDAS differs 
from CFS-associated MiDAS in that it is not tightly linked 
to the appearance of fragility.
MiDAS at telomeres is predominantly a 
conservative form of DNA synthesis
CFS-associated MiDAS has been shown to occur 
predominantly via a conservative form of DNA synthesis 
that leads to EdU incorporation on only one of the two 
sister chromatids of a mitotic chromosome. Furthermore, 
the ALT mechanism has been shown to utilize a 
conservative form of DNA synthesis [13]. To investigate 
whether telomeric MiDAS was similarly conservative, 
we quantified the relative proportions of mitotic EdU foci 
that were present on either a single sister chromatid or 
both chromatids. We observed that EdU incorporation at 
telomeres in both U2OS and HeLa cells occurs primarily 
in a conservative manner irrespective of whether the 
cells were exposed or not to replication stress (Figure 
3E, 3F). We also investigated if there is a correlation 
between telomere fragility and whether the DNA synthesis 
occurred via a conservative or a semi-conservative 
process. However, we failed to observe any correlation in 
either untreated or APH-treated U2OS cells. For example, 
in the case of APH-treated cells, 20% of the events were 
conservative and associated with fragility, while 18% were 
non-conservative but fragile. For the remaining 62% of 
events that occurred on non-fragile telomeres, 29% were 
conservative while 33% were non-conservative. 
Telomeric MiDAS utilizes some, but not all, of 
the same factors as CFS-MiDAS
MiDAS at CFSs is proposed to be a BIR-like 
process that is mediated by a RAD52-dependent, but 
RAD51-independent, form of homologous recombination. 
In addition, CFS-MiDAS has a strong requirement for the 
SLX4 scaffold protein and its associated endonuclease 
MUS81-EME1 [14, 15, 18]. To investigate the mechanism 
for telomeric MiDAS, we chose to focus on U2OS cells 
due to the high levels of telomeric MiDAS exhibited by 
these cells. We individually depleted SLX4, RAD52 and 
MUS81 in U2OS cells. In agreement with previous data 
on CFSs, we observed that SLX4 and RAD52 are required 
for telomeric MiDAS (Figure 4A, 4B and Supplementary 
Figure 4A, 4B). However, in contrast to CFS-associated 
MiDAS (Figure 4C), the MiDAS occurring at telomeres 
was apparently independent of MUS81-EME1 in U2OS 
cells (Figure 4D and Supplementary Figure 4A). To 
further confirm this in a non-ALT cell line, we chose 
HeLaLT cells and depleted MUS81 using two previously 
validated siRNAs. Similarly to U2OS cells, we observed 
that telomeric MiDAS in HeLaLT cells does not require 
MUS81 (Figure 4E and Supplementary Figure 4C).
DISCUSSION
Oncogene-induced DNA replication stress is a key 
driver of chromosomal instability in human cancer, and is 
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Figure 2: Spontaneous MiDAS at telomeres is not limited to ALT-associated telomeres. (A) Representative images and 
quantification of EdU (red) incorporation at telomeres (marked by telomeric FISH; green) on metaphase chromosomes (stained with DAPI; 
blue) in a series of (B) ALT and (C) telomerase positive cell lines with and without low dose APH. Data represent the means of at least three 
independent experiments. Error bars indicate SEM. See also Supplementary Figure 2.
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Figure 3: Replication stress induced telomeric MiDAS does not correlated with telomere fragility. Quantification of 
telomeric EdU foci associated with either morphologically fragile or normal telomeres in (A) untreated U2OS cells or low dose APH-
treated U2OS and (B) HeLa cells. (C) Representative images and (D) quantification of EdU incorporation (red) at telomeres (marked 
by telomeric FISH; green) on metaphase chromosomes (DAPI stained; blue) in U2OS cells. Where indicated, cells were exposed to low 
dose APH and 5 μM ATRi. Quantification of telomeric EdU foci located either on a single chromatid or on both chromatids in (E) APH-
treated HeLa cells and (F) U2OS cells in both untreated or APH-treated conditions. Data represent the means of at least three independent 
experiments. Error bars indicate SEM. See also Supplementary Figure 3.
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Figure 4: Telomeric MiDAS is also SLX4- and RAD52-dependent, but independent of MUS81. (A) Representative images 
EdU (red) incorporation at telomeres (marked by telomeric FISH; green) on metaphase chromosomes (stained with DAPI; blue) in control, 
SLX4-, RAD52-, or MUS81-depleted U2OS, as indicated. (B–D) Quantification of total EdU incorporation (combined telomeric and non-
telomeric) and EdU incorporation specifically at telomeres in U2OS cells. (E) Quantification of EdU incorporation specifically at telomeres 
in HeLa-LT cells. EdU was quantified on metaphase chromosomes following the indicated siRNA depletions. Data represent the means of 
at least three independent experiments. Error bars indicate SEM. See also Supplementary Figure 4.
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proposed to play a direct role in oncogenesis [19, 20]. It 
is imperative, therefore, that we understand not only the 
causes of replication stress, but also the pathways used by 
cells to counteract its potentially oncogenic effects. When 
challenged by replication stress, the replication program at 
CFSs is often disturbed to such an extent that they continue 
to undertake DNA synthesis even after the cell has entered 
early mitosis. Recent data indicate that this mitotic DNA 
synthesis (MiDAS) is not conventional, semi-conservative 
replication, but rather is a recombinational repair-driven 
process that resembles BIR in yeast. In this article, 
we have investigated the role of MiDAS at telomeres. 
This was undertaken because telomeres resemble CFSs 
and present a severe challenge to the DNA replication 
machinery due to their sequence, structure, tightly-bound 
proteins, and unidirectional replication. 
We have shown that MiDAS occurs at telomeres, 
and is significantly activated by prior APH-induced 
replication stress. Moreover, our data indicate that 
telomeric MiDAS and CFS MiDAS can proceed via a 
RAD52-dependent, conservative form of DNA synthesis, 
and largely utilize a common set of factors. Nevertheless, 
there are significant differences between the behaviour 
of CFSs and telomeres under replication stress. The 
most notable of these are the lack of a requirement for 
MUS81 for telomeric MiDAS, and a lack of a correlation 
between MiDAS and the presence of overt fragility. A 
form of micro-homology mediated BIR (MMBIR) has 
been proposed as the mechanism of MiDAS at CFSs, 
which relies on MUS81-EME1 to promote template 
switching. There are two potential explanations for the 
lack of requirement for MUS81 in telomeric MiDAS. 
First, because telomeres already comprise repetitive 
sequences, MMBIR-associated template switching might 
not be required. Second, the telomere-associated 3-way 
junction generated as an intermediate during BIR might 
not require to be resolved at all because it could potentially 
branch migrate until the end of the chromosome. Although 
our data are consistent with the proposal that telomeres 
represent bona fide fragile sites in the human genome, we 
observed a tendency for APH-induced MiDAS to occur 
at telomeres with a morphologically normal appearance. 
This was the case for both U2OS cells (ALT) and HeLa 
cells (telomerase+). Hence, it is clear that the presence 
of telomeric MiDAS and fragility correlate poorly, and 
should not be viewed as surrogates of one another. 
Recently, a form of POLD3-dependent DNA 
synthesis was reported to occur at telomeres in the 
absence of replication stress, which was termed break-
induced telomere synthesis. This process resembles the 
telomeric MiDAS that we report here, but with one crucial 
difference: the telomeric DNA synthesis was observed 
only in ALT cells, and not in telomerase+ cells, and 
was therefore considered to be the mechanism by which 
ALT occurs [11]. In contrast, we consistently observed 
telomeric MiDAS in both telomerase+ and ALT cell lines. 
Therefore, telomeric MiDAS is not specific for cells with 
ALT-mediated telomere maintenance, but instead appears 
to be a general feature influenced by numerous telomere-
associated features, including telomere length, as well as 
the extent of aneuploidy in cells. These features would 
potentially create a challenge to the faithful replication of 
a telomere and increase the probability that fork stalling 
and associated DNA damage would occur during S phase. 
Taken together with the previously published results, our 
data underline how both intrinsic factors (telomere length 
and aneuploidy) and extrinsic factors (APH-induced 
replication stress and DSB induction), but not ALT per 
se, are the main drivers of MiDAS. Interestingly, given 
the association of replication stress with oncogenesis, the 
existence of high levels of telomeric (and CFS-associated) 
MiDAS levels in the SV40-transformed VA13 fibroblast 
line indicates that neoplastic transformation is not a 
prerequisite for the existence of the MiDAS pathway.
Recently, Min et al. [11, 21] reported a telomeric 
MiDAS pathway that was proposed to underlie the ALT 
mechanism. These authors showed that ALT-associated 
MiDAS occurring in the absence of replication stress 
is a RAD51- and BRCA2-independent pathway that 
utilizes RAD52. Moreover, these authors showed that 
the G-quadruplex stabilizing agent, pyridostatin, induces 
telomeric MiDAS in both ALT and telomerase+ cells, 
presumably through stabilizing G-quadruplexes within 
telomeric DNA that then generates localized replication 
stress. These data on ALT cells correspond with ours, 
but we additionally have shown that this pathway can 
be responsible for high levels of basal (as well as APH-
induced) telomeric MiDAS in certain telomerase+ cells. In 
addition, Min et al. concluded that basal telomeric MiDAS 
is ATR-dependent, while we find (as for CFS-associated 
MiDAS) that ATR suppresses telomeric MiDAS both 
untreated and APH-treated cells. The reasons for these 
discrepancies are not clear at this stage. Indeed, we 
propose that aneuploidy is a key driver of MiDAS both at 
telomeres and CFSs, which further supports the notion that 
the use of MiDAS inhibitors could be a promising strategy 
for anti-cancer therapy [14]. 
MATERIALS AND METHODS
Cell culture
U2OS, VA13, and Saos2 were used as examples of 
ALT positive cell lines, and HeLa, HeLaLT, HT29, and 
T98G were used as examples telomerase positive cell 
lines. U2OS, HeLa, and HT29 cells were obtained from 
the ATCC. Saos2, VA13, T98G cells were provided by 
Dr. J. Pena Diaz (University of Copenhagen, Denmark), 
and HeLaLT cells were provided by Dr. J. Karlseder 
(Salt Institute, USA). All cell lines were maintained 
in Dulbecco’s modified Eagle’s medium (GlutaMAX; 
Thermo Scientific) supplemented with 10% fetal bovine 
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serum (Life Technologies) and 1% penicillin/streptomycin 
(Thermo Scientific) at 37° C in a humidified atmosphere 
with 5% CO2. The cells were screened regularly for 
mycoplasma using a MycoAlert Mycoplasma Detection 
Kit (Lonza), and found to be negative.
Cell synchronization and treatment
For the synchronization and aphidicolin treatment 
of the cells, a protocol described previously [14, 15] was 
used with minor modifications. Briefly, the cells were 
treated with or without 0.4 μM APH (Sigma-Aldrich) 
for 16 hrs. Cells were synchronized in the late G2 phase 
with the CDK1 inhibitor RO3306 (7 μM; APExBIO, [22]) 
either simultaneously or during the last 8 hrs of the APH 
treatment. The cells were then released from this arrest by 
washing 3× with PBS at room temperature, and were then 
allowed to progress into metaphase at 37° C for 45–60 
minutes in the presence of 20 μM EdU (Life Technologies) 
and 100 ng/ml KaryoMAX Colcemid Solution in HBBS 
(Life Technologies). Where stated, in addition to EdU 
and Colcemid, the cells were also released into medium 
containing high dose APH (2 μM). To prepare metaphase 
chromosome spreads, mitotic cells were shaken off and 
collected by centrifugation.
Where required, ATR activity was inhibited using 
5 μM VE-821 (SML1415; Sigma-Aldrich) for 16 hrs 
 [14, 23]. VE-821 was added at the same time as the low 
dose APH, but was kept in the medium after release of 
cells into mitosis. 
RNA interference
The following siRNAs were used: SLX4 
(5′-GAGAAGAACCCUAAUGAAA-3′ and 5′-GCACAA 
GGGCCCAGAACAA-3′; Sigma Aldrich, published 
previously in [24], RAD52 (5′-GGUCAUCGGGUAAU 
UAAUC-3′; J-011760-06-0010, Dharmacon), MUS81 
(#1: 5′-CCUAAUGGUCACCACUUCUUA-3′ and 
#2: 5′-GAGUUGGUACUGGAUCACAUU-3′; Sigma 
Aldrich, previously published in [25]), and non-targeting 
siRNA (D-001810-10-20; Dharmacon ON-TARGETplus 
pool). Cells were transfected with the indicated siRNAs 
using Lipofectamine RNAimax transfection reagent (Life 
Technologies).
Metaphase spreads
Cells arrested in G2 by exposure to 7 μM RO3306 
(APExBIO; [22]) were released into mitosis in the 
presence of 100 ng/ml KaryoMAX Colcemid Solution in 
HBBS (Life Technologies). Mitotic cells were collected 
and harvested by centrifugation at 300 g for 5 minutes. 
The cells were swollen with pre-warmed 37.5 mM KCl at 
37° C for 20–30 minutes, and were then harvested at 250 g 
for 5 minutes. Ice-cold methanol:acetic acid (3:1) was used 
to fix the cells at –20° C for overnight. Fixed cells were re-
suspended in fresh fixative and dropped onto pre-cooled 
damp slides to make chromosome spreads. The slides 
were aged either at room temperature for a week, at 42° C 
overnight or at 65° C for 10 minutes before Telomeric 
FISH analysis and/or EdU detection (see below).
Telomeric FISH
A FAM-labeled, C-rich PNA telomere probe 
(Panagene) was used for telomeric FISH according to the 
manufacturer’s protocol with the following modifications: 
1X blocking reagent (11096176001, Roche) was added 
into the hybridization buffer, probe incubation was 
performed at 37° C for at least 2 hours, and the slides were 
incubated in Washing Solution I (PBS with 0.1% Tween 
20, pre-warmed at 57° C) for 3 × 10 min. Following the 
FISH analysis, EdU detection (see below) was performed 
after re-fixation with 4% formaldehyde in PBS for 
4 minutes at room temperature.
EdU labeling and detection
Cells were pulse labeled with 20 μM EdU (Life 
Technologies) for 45–60 minutes after release from an 
RO3306 arrest. Metaphase chromosomes were isolated 
(see above) and EdU detection was performed with 
a Click-IT EdU Alexa Flour 594 Imaging kit (Life 
Technologies), as described previously [14]. 
Microscopy analysis
Images were captured with an Olympus BX63 
microscope and the images were then analyzed using 
Olympus CellSens software.
Antibodies
The primary antibodies and their dilutions for 
Western blotting analysis were RAD52 (1:100 Santa Cruz 
sc-8350, or 1:500 Abcam ab103067), SLX4 (1:200, S714C 
raised against the residues 1535-1834, a gift from Dr. J. 
Rouse, University of Dundee, UK), MUS81 (1:1000, Santa 
Cruz sc-53382), histone H3 (1:2000, Abcam ab1791), actin 
(1:1000, Sigma-Aldrich A3853), and β-tubulin (1:1000, 
T4026; Sigma Aldrich). The secondary antibodies used 
were goat anti-rabbit IgG (1:5000, Sigma-Aldrich A6667), 
goat anti-mouse IgG (1:5000, Sigma Aldrich A4416), and 
donkey anti-sheep IgG (1:5000, Sigma Aldrich A3415).
Western blotting analysis
The cells were lysed with high-salt RIPA buffer 
(50 mM Tris-HCl, pH7.5, 420 mM NaCl, 1.0% NP-40, 
0.5% deoxycholate, 0.1% SDS, 10% glycerol) containing 
protease inhibitor cocktail (cOmplete EDTA-free protease 
inhibitor cocktail tablets; Roche) for 30 minutes on ice. 
A BCA protein assay kit (Thermo Fisher Scientific) was 
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used to measure protein concentration according to the 
manufacturer’s instructions. The protein samples were 
run on 4–12% or 12% NuPAGE Bis-Tris gels (Life 
Technologies) with NuPAGE MOPS SDS running buffer 
(Life Technologies), and were transferred to a PVDF 
membrane (Amersham Hybond PVDF membrane; VWR) 
using wet transfer. The primary antibody incubation was 
performed for 16 hours at 4° C following blocking of the 
membrane in 5% milk in PBS-T (0.1% Tween 20 in PBS) 
for 1 hour at room temperature. After washing in PBS-T, 
the membrane was incubated with the secondary antibody 
for 30 minutes at room temperature. The membrane was 
washed and incubated with Luminata Forte Western HRP 
Substrate (Millipore) for signal detection. The western blot 
images were captured using an Amersham Imager 600 and 
quantified with Fiji software (GE Life Sciences).
Statistical analysis
Statistical significance was calculated using a 
Mann-Whitney test for unpaired and nonparametric data 
with GraphPad Prism Software (version 6). 
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